Filing Details
- Accession Number:
- 0001181431-13-030396
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-23 21:00:29
- Reporting Period:
- 2013-05-21
- Filing Date:
- 2013-05-23
- Accepted Time:
- 2013-05-23 21:00:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1017491 | Apricus Biosciences Inc. | APRI | Pharmaceutical Preparations (2834) | 870449967 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1283304 | G Kleanthis Xanthopoulos | 11975 El Camino Real, Suite 300 San Diego CA 92130 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2013-05-21 | 2,864 | $3.36 | 75,783 | No | 4 | S | Indirect | By Kleanthis & Gaylen Xanthopoulos TTEES, Xanthopoulos Family Trust Dtd 9/30/2011 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Kleanthis & Gaylen Xanthopoulos TTEES, Xanthopoulos Family Trust Dtd 9/30/2011 |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
Billionaire Hedge Funds
